Day 1 – 9 July 2012

• The global value chain for TB diagnostics and current pipeline (by M Pai) [Slides]
• Value chain in action: Xpert MTB/RIF (by C Boehme) [Slides]
• Value chain in action: TB serology (by M Pai) [Slides]
• Enabling POC Diagnostics through Standard-Setting (by G Walther) [Slides]

Day 2 – 10 July 2012

• Incremental value of new diagnostics (by M Pai & G Alvarez) [Slides]
• Impact of test results on diagnostic and clinical decisions (by M Pai & D Ling) [Slides]
• Reference standards: Brief presentations & panel discussion
  • Microscopy studies (by A Ramsay) [Slides]
  • Molecular assays (by C Boehme) [Slides]
  • IGRAs (by D Menzies) [Slides]
  • Pediatric TB (by P Jean-Philippe) [Slides]
  • Extrapulmonary TB (by M Caws) [Slides]
• Statistical approaches for dealing with imperfect reference standards (by N Dendukuri) [Slides]
• Impact on patient outcomes: intro to diagnostic RCTs (by M Pai) [Slides]
• Diagnostic RCTs: ccase study on microscopy (by A Ramsay) [Slides]
• Clinical impact of Xpert MTB/RIF (by A Cattamanchi) [Slides]

Day 3 – 11 July 2012

• Operational and implementation research: an overview (by A Ramsay) [Slides]
• Implementation research: case study: Improving case detection in Uganda (by A Cattamanchi) [Slides]
• Implementation research: case study: LED microscopy (by J Minion) [Slides]
• Implementation research: case study: IGRA reproducibility (by N Banaei) [Slides]
• TB diagnostic end-points in vaccine trials (by M Behr) [Slides]
• Deployment of POC technologies: where, why and what impact? (by K Palamountain) [Slides]
• Optimism bias in TB diagnostic package inserts (by C Denkinger) [Slides]
• Market for TB diagnostics: case study from India (by M Chitalia) [Slides]
• Qualitative research on TB diagnostics (by N Engel) [Slides]

Day 4 – 12 July 2012

• Systematic reviews of diagnostic accuracy (by K Steingart) [Slides]
• SR: case study: LAM (by J Minion) [Slides]
• SR: case study: Xpert MTB/RIF & DST for 1st and 2nd line drugs (by K Steingart) [Slides]
• SR: case study: Oral versus blood-based HIV testing (by N Pant Pai) [Slides]
• Guideline development in TB diagnostics (by K Steingart) [Slides]
• IGRA guidelines: concordance, discordance or confusion? (by C Denkinger) [Slides]
• Mathematical modeling: an introduction (by D Dowdy) [Slides]

Day 5 – 13 July 2012

• Modeling of TB diagnostics: case studies (by D Dowdy) [Slides]
• Case study: economic models of IGRAs (by O Oxlade) [Slides]
• Cost-effectiveness analysis (by D Dowdy) [Slides]
• Modeling & cost-effectiveness: challenges and future directions (by D Dowdy) [Slides]
• Stepped wedge, phased implementation designs (by D Dowdy) [Slides]